Gothenburg, June 8, 2026 - The Nomination Committee of Elicera Therapeutics AB (publ) proposes Margareth Jorvid as the new Chair of the Board. Agneta Edberg, who has served as Chair since 2021, has announced that she wishes to step down from the Chair position but is standing for re-election as an ordinary board member.
Agneta Edberg comments:
"After seven years on the Board, six of which as Chair, I believe it is time for a change in the leadership of the Board. I am very proud of what Elicera has achieved during these years and look forward to continuing to contribute as an ordinary board member. Margareth will be an excellent Chair."
Margareth Jorvid comments:
"I am honored and very pleased to be proposed as Chair of the Board. Elicera is in an exciting phase with promising clinical results and a unique platform in cell and gene therapy. I look forward to leading the Board in its work to develop the company and maximize the value of its strong scientific foundation for the benefit of patients and shareholders."
Other proposals from the Nomination Committee:
The Nomination Committee further proposes the re-election of Cedra Väst KB as auditor, with Kristoffer Håkansson as the auditor in charge.
Proposed fees:
The Nomination Committee has consisted of Magnus Essand (Chair), Di Yu and Jamal El-Mosleh, who together represented approximately 20 percent of the votes prior to the latest share issue.
The Annual General Meeting will be held on 25 June 2026 at 13:00 at Advokatfirman Delphi's offices in Stockholm, Mäster Samuelsgatan 17.
This press release has been approved by the Board of Directors and the CEO for publication. The information was submitted, through the care of the contact person below, for public release on 8 June 2026 at 08:40 CET.